Generic Applications With Paragraph IV Filings, In Brief
Barr challenges Eloxatin patent: Barr Pharmaceuticals has filed an ANDA with a Paragraph IV certification - by which an ANDA sponsor contends that a patent is invalid, unenforceable, or will not be infringed by the generic - for Sanofi-Aventis' Eloxatin (oxaliplatin). There are currently no generic versions of the drug, and Sanofi filed suit Jan. 4 to initiate patent litigation. There are four patents listed in FDA's Orange Book for 5mg/mL Eloxatin, the last of which expires in Feb. 2016. The colorectal cancer agent is covered by pediatric exclusivity until Feb. 9, 2008...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth